Clinical Trial Detail

NCT ID NCT02438007
Title A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
Recruitment Terminated
Gender male
Phase Phase III
Variant Requirements No
Sponsors Tokai Pharmaceuticals
Indications

prostate cancer

Therapies

galeterone

Enzalutamide

Age Groups: adult

No variant requirements are available.